Analysis of emergence of quinolone-resistant gonococci in Greece by combined use of Neisseria gonorrhoeae multiantigen sequence typing and multilocus sequence typing.
The prevalence of quinolone-resistant Neisseria gonorrhoeae (QRNG) in Greece remained low from 1997 to 2003 but increased dramatically from 11% to 56% between 2004 and 2007. N. gonorrhoeae multiantigen sequence typing (NG-MAST) and multilocus sequence typing (MLST) were used to investigate trends in quinolone resistance from 1997 to 2007 and explore the origins of the recent increase in QRNG. We characterized 295 QRNG isolates from the study period and 233 quinolone-susceptible (QS) gonococci from 2004 and 2005, when the rapid increase in QRNG occurred. From 1997 to 1999, an outbreak of QRNG was due to the dissemination of isolates of serovar Arst that belonged to two closely related genotypes. Few QRNG isolates, of diverse genotypes, were present between 2001 and 2003, whereas the sharp increase in QRNG from 2004 onwards was due to the appearance of serovar Bropyst isolates of several major NG-MAST sequence type (STs) that previously had not been identified in Greece. These isolates were shown by MLST to be variants of a single multiply antibiotic-resistant QRNG strain (ST1901) that appeared in Greece and rapidly diversified into 31 NG-MAST STs. There were no isolates of MLST ST1901 or any of the 31 NG-MAST STs among QS isolates from 2004 and 2005 or among 8 representatives of multiresistant but quinolone-susceptible serovar Bropyst isolates circulating in Greece during the 1990 s, supporting the view that the recent increase in QRNG was due to importation of a QRNG strain(s) of MLST ST1901 into Greece. Recently, multiresistant QRNG isolates of ST1901 with reduced susceptibility to the newer cephalosporins have appeared in Greece.
Department of Infectious Disease Epidemiology, Imperial College London, St. Mary's Hospital Campus, Norfolk Place, London W2 1PG, United Kingdom.
Angeliki
A
Mavroidi
Eva
E
Tzelepi
Eirini
E
Siatravani
Daniel
D
Godoy
Vivi
V
Miriagou
Brian G
BG
Spratt
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015373:Bacterial Typing Techniques; D024881:Drug Resistance, Bacterial; D005838:Genotype; D006069:Gonorrhea / Q000453:epidemiology* / Q000382:microbiology; D006115:Greece / Q000453:epidemiology; D006801:Humans; D017720:Molecular Epidemiology; D058889:Molecular Typing; D058885:Multilocus Sequence Typing; D009344:Neisseria gonorrhoeae / Q000145:classification* / Q000187:drug effects* / Q000302:isolation & purification; D015363:Quinolones / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D015363:Quinolones
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3140-5
9501229
J Antimicrob Chemother. 2006 Apr;57(4):775-9
16492719
Sex Transm Infect. 2005 Oct;81(5):403-7
16199740
Sex Transm Dis. 1991 Oct-Dec;18(4):238-44
1771478
Lancet. 2006 Jul 8;368(9530):139-46
16829298
Sex Transm Dis. 1997 Jul;24(6):378-85
9243747
J Antimicrob Chemother. 2008 Sep;62(3):637-9
18556708
J Clin Microbiol. 2006 Aug;44(8):2689-97
16891479
Sex Transm Dis. 2006 Jun;33(6):357-60
16572037
BMC Biol. 2007 Sep 07;5:35
17825091
Mol Ecol. 2000 Oct;9(10):1657-9
11050560
J Infect Dis. 2005 Oct 1;192(7):1191-5
16136461
Antimicrob Agents Chemother. 2010 Mar;54(3):1060-7
20028823
J Infect Dis. 2004 Apr 15;189(8):1497-505
15073688
J Clin Microbiol. 2009 Nov;47(11):3540-5
19794054
Antimicrob Agents Chemother. 2001 Sep;45(9):2651-4
11502546
APMIS. 2007 Mar;115(3):231-41
17367469
J Clin Microbiol. 2000 Sep;38(9):3489-91
10970412
J Clin Microbiol. 2002 Oct;40(10):3741-9
12354874
Sex Transm Infect. 2006 Jun;82(3):225-6
16731673
Sex Transm Dis. 2006 Jan;33(1):8-10
16385215
Sex Transm Dis. 2010 Feb;37(2):115-20
19901866
J Clin Microbiol. 2009 Feb;47(2):489-91
19052176
Mol Biol Evol. 2007 Aug;24(8):1596-9
17488738
Swiss Med Wkly. 2008 Apr 19;138(15-16):223-4
18431696
Mol Biol Evol. 2005 Sep;22(9):1887-902
15944444